Back to Browse Journals » International Journal of Women's Health » Volume 1

Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy

Authors SA Kingsberg, S Kellogg, M Krychman

Published Date August 2009 Volume 2009:1 Pages 105—111

DOI http://dx.doi.org/10.2147/IJWH.S4872

Published 20 August 2009

SA Kingsberg¹, S Kellogg², M Krychman³

1University Hospitals Case Medical Center, Case Western Reserve University Cleveland OH, USA; 2The Pelvic and Sexual Health Institute of Philadelphia, Drexel University College of Medicine, Philadelphia, USA; 3Southern California Center for Sexual Health and Survivorship Medicine, Newport Beach, CA, USA

Abstract: Vulvovaginal atrophy (VVA) and dryness are common symptoms of the decline in endogenous production of estrogen at menopause and often result in dyspareunia. Yet while 10% to 40% of women experience discomfort due to VVA, it is estimated that only 25% seek medical help. The main goals of treatment for vaginal atrophy are to improve symptoms and to restore vaginal and vulvar anatomic changes. Treatment choices for postmenopausal dyspareunia resulting from vulvovaginal atrophy will depend on the underlying etiology and might include individualized treatment. A number of forms of vaginal estrogen and manner of delivery are currently available to treat moderate to severe dyspareunia caused by VVA. They all have been shown to be effective and are often the preferred treatment due to the targeted efficacy for urogenital tissues while resulting in only minimal systemic absorption. Both healthcare professionals and patients often find it difficult to broach the subject of sexual problems associated with VVA. However, with minimal effort to initiate a conversation about these problems, healthcare providers can provide useful information to their postmenopausal patients in order to help them each choose the optimal treatment for their needs and symptoms.

Keywords: dyspareunia, postmenopausal vulvovaginal atrophy, vaginal estrogen therapy

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Wine consumers’ environmental knowledge and attitudes: Influence on willingness to purchase

Nelson Barber, Christopher Taylor, Sandy Strick

International Journal of Wine Research 2009, 1:59-72

Published Date: 9 February 2009

Eggshell membrane: A possible new natural therapeutic for joint and connective tissue disorders. Results from two open-label human clinical studies

Kevin J Ruff, Dale P DeVore, Michael D Leu, Mark A Robinson

Clinical Interventions in Aging 2009, 4:235-240

Published Date: 18 May 2009

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

Prolonged rupture of membranes in term infants: should all babies be screened?

Christopher Flannigan, Martina Hogan

Clinical Audit 2010, 2:1-6

Published Date: 9 February 2010

Diagnosis and management of pre-eclampsia: an update

Judi A Turner

International Journal of Women's Health 2010, 2:327-337

Published Date: 30 September 2010

Emerging options in growth hormone therapy: an update

Kemp SF, Frindik JP

Drug Design, Development and Therapy 2011, 5:411-419

Published Date: 30 August 2011

Transforming nanostructured chitin from crustacean waste into beneficial health products: a must for our society

Morganti P, Morganti GGM, Morganti AAM

Nanotechnology, Science and Applications 2011, 4:123-129

Published Date: 6 December 2011

Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy

Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I

Neuropsychiatric Disease and Treatment 2012, 8:85-93

Published Date: 9 February 2012

Osteoblasts and their applications in bone tissue engineering

Rupani A, Balint R, Cartmell SH

Cell Health and Cytoskeleton 2012, 4:49-61

Published Date: 8 May 2012

Changes in cervical cancer screening behavior for women attending Pap Test Week clinics

Poliquin V, Decker K, Altman AD, Lotocki R

International Journal of Women's Health 2013, 5:141-148

Published Date: 8 April 2013